1. Home
  2. CCM vs NEUP Comparison

CCM vs NEUP Comparison

Compare CCM & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concord Medical Services Holdings Limited

CCM

Concord Medical Services Holdings Limited

HOLD

Current Price

$4.52

Market Cap

23.8M

Sector

Health Care

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.05

Market Cap

21.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCM
NEUP
Founded
1997
1996
Country
China
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.8M
21.7M
IPO Year
2009
N/A

Fundamental Metrics

Financial Performance
Metric
CCM
NEUP
Price
$4.52
$4.05
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
12.0K
51.8K
Earning Date
09-26-2025
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$51,056,841.00
$15,649,448.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.54
$3.65
52 Week High
$10.77
$21.40

Technical Indicators

Market Signals
Indicator
CCM
NEUP
Relative Strength Index (RSI) 48.25 46.98
Support Level $4.08 $3.98
Resistance Level $5.40 $4.18
Average True Range (ATR) 0.61 0.20
MACD 0.01 0.05
Stochastic Oscillator 31.25 41.32

Price Performance

Historical Comparison
CCM
NEUP

About CCM Concord Medical Services Holdings Limited

Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: